| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| KE:288 | Activation of specific nuclear receptors, Transcriptional change | ||||||
| AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal system disease | Under Development | Mouse, Rat | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
| AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory system disease | Under Development | Human, Mouse | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary system disease | WPHA/WNT Endorsed | Mouse, Human | 0.2 | KE:272 | Activation/Proliferation, T-cells |
| AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal system disease | Under Review | Rattus sp. ABTC 42503, Mus sp. 2000082 | 0.6 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
| KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | ||||||
| KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | ||||||
| AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | Mouse, Zebrafish, Rats, Human | 0.2 | KE:28 | Reduction, Angiogenesis |
| AOP:100 | Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior | Reproductive system disease | - | Goldfish | 0.14 | KE:672 | Reduced, Prostaglandin F2alpha synthesis, ovary |
| AOP:101 | Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release | Reproductive system disease | - | Goldfish | 0.14 | KE:681 | Decreased, Prostaglandin F2alpha synthesis, ovary |
| AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.17 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
| AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal system disease | Under Review | Rattus norvegicus, Mus musculus | 0.2 | KE:716 | Increase, cell proliferation (hepatocytes) |
| AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory system disease | - | Mus musculus | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
| AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.14 | KE:739 | Increase, Hypertrophy and proliferation (follicular cell) |
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.17 | KE:111 | Agonism, Estrogen receptor |
| AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | Rattus norvegicus | 0.17 | KE:778 | Increase, Regenerative cell proliferation (corneal cells) |
| AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | Mus musculus, Rattus norvegicus | 0.2 | KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) |
| AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary system disease | - | Rattus norvegicus | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
| AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | Under Development | Mus musculus, Rattus norvegicus | 0.25 | KE:716 | Increase, cell proliferation (hepatocytes) |
| AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary system disease | - | Mus musculus, Rattus norvegicus | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign neoplasm; Respiratory system disease | Under Review | 0.14 | KE:870 | Increase, Cell Proliferation | |
| AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular system disease | Under Development | Human, Mouse, Rat, Cow | 0.1 | KE:933 | KE6 : Depletion, Nitric Oxide |
| AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive system disease | - | CD-1 mouse, SD rat | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 0.29 | KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells |
| KE:1065 | Activation, estrogen receptor alpha | ||||||
| AOP:190 | Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.17 | KE:1829 | Altered, Thyroid hormone-dependent gene expression |
| AOP:191 | Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:1829 | Altered, Thyroid hormone-dependent gene expression |
| AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive system disease | - | Caenorhabditis elegans | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| KE:1262 | Apoptosis | ||||||
| AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal system disease | WPHA/WNT Endorsed | Rodents, Homo sapiens | 0.4 | KE:1393 | Hepatocytotoxicity |
| KE:1394 | Induction, persistent proliferation/sustained proliferation | ||||||
| AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.14 | KE:870 | Increase, Cell Proliferation |
| AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | Lemna minor, Daphnia magna, Danio rerio | 0.25 | KE:1821 | Decrease, Cell proliferation |
| AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine system disease | - | Human, Rat | 0.12 | KE:1614 | Decrease, androgen receptor activation |
| AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | Daphnia magna | 0.25 | KE:1821 | Decrease, Cell proliferation |
| AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | Mammals | 0.29 | KE:870 | Increase, Cell Proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:305 | 5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | Rat, Human, Mouse | 0.2 | KE:1614 | Decrease, androgen receptor activation |
| AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | Daphnia magna, Fish | 0.14 | KE:1115 | Increase, Reactive oxygen species |
| AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary system disease | - | Rat | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
| AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular system disease | Under Development | Homo sapiens | 0.14 | KE:1869 | Diminished protective oxidative stress response |
| AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal system disease; Respiratory system disease | Under Development | 0.33 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1172 | Increased activation, Nuclear factor kappa B (NF-kB) | ||||||
| AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal system disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary system disease | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive system disease | - | Lemna minor, Chlamydomonas reinhardtii | 0.12 | KE:1115 | Increase, Reactive oxygen species |
| AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive system disease | - | Lemna minor | 0.12 | KE:1115 | Increase, Reactive oxygen species |
| AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | Zebrafish | 0.12 | KE:1821 | Decrease, Cell proliferation |
| AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.17 | KE:1869 | Diminished protective oxidative stress response | |
| AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.25 | KE:870 | Increase, Cell Proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | Fish, Mice | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory system disease | - | 0.2 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory system disease | - | 0.25 | KE:1262 | Apoptosis | |
| AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.25 | KE:870 | Increase, Cell Proliferation | |
| AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic system disease; Cancer | - | Homo sapiens, Mus musculus | 0.09 | KE:870 | Increase, Cell Proliferation |
| AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic disease; Cancer | Under Development | Humans, Mice | 0.33 | KE:1971 | Increased, tumor growth |
| KE:1241 | Increased, Motility | ||||||
| KE:1262 | Apoptosis | ||||||
| AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital nervous system abnormality; Nervous system disease | - | Homo sapiens, Mus musculus musculus, Rattus norvegicus | 0.14 | KE:1262 | Apoptosis |
| AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic disease; Cancer | Under Development | Human and other cells in culture, Human, Mice, Rat, Canine heartworm nematode, Yeast | 0.2 | KE:112 | Antagonism, Estrogen receptor |
| KE:1172 | Increased activation, Nuclear factor kappa B (NF-kB) | ||||||
| AOP:449 | Ceramide synthase inhibition leading to neural tube defects | Neural tube defect | - | 0.14 | KE:1502 | Histone deacetylase inhibition | |
| AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | Human | 0.22 | KE:870 | Increase, Cell Proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory system disease | - | 0.09 | KE:1262 | Apoptosis | |
| AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | Mouse | 0.22 | KE:1821 | Decrease, Cell proliferation |
| KE:1262 | Apoptosis | ||||||
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:748 | Increased, Estrogen receptor (ER) activity | |
| AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous system disease; Monogenic disease | Under Review | Human, Mouse, Rat, Rhesus monkeys, Rabbit, Guinea pig | 0.1 | KE:870 | Increase, Cell Proliferation |
| AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | Mouse | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:1262 | Apoptosis | ||||||
| AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive system disease | - | Mammals, Fish | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive system disease; Cancer | - | 0.22 | KE:854 | Alterations, Cellular proliferation / hyperplasia | |
| KE:1183 | Decreased, Apoptosis (Epithelial Cells) | ||||||
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.29 | KE:1115 | Increase, Reactive oxygen species |
| KE:1262 | Apoptosis | ||||||
| AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | Murinae gen. sp. | 0.14 | KE:1115 | Increase, Reactive oxygen species |
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.11 | KE:1262 | Apoptosis |
| AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive system disease; Endocrine system disease | - | Rat, Mouse, Zebra fish, Human | 0.17 | KE:1262 | Apoptosis |
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.25 | KE:885 | Increase, Cancer |
| AOP:205 | AOP from chemical insult to cell death | Unclassified | - | Vertebrates | 0.17 | KE:1262 | Apoptosis |
| AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | Rattus rattus, Mus musculus | 0.22 | KE:1193 | N/A, Breast Cancer |
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | 0.22 | KE:1193 | N/A, Breast Cancer | |
| KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | ||||||
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | Mammals | 0.33 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.5 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | Vertebrates | 0.2 | KE:1065 | Activation, estrogen receptor alpha |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:19 | Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) | Reproductive system disease | - | 0.2 | KE:26 | Antagonism, Androgen receptor | |
| AOP:30 | Estrogen receptor antagonism leading to reproductive dysfunction | Unclassified | Under Review | Zebra danio, Fathead minnow, Medaka | 0.17 | KE:112 | Antagonism, Estrogen receptor |
| AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive disorder | WPHA/WNT Endorsed | Human, Rat, Mouse | 0.12 | KE:279 | Thyroperoxidase, Inhibition |
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 0.29 | KE:494 | Glucocorticoid Receptor Agonist, Activation |
| KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells | ||||||
| AOP:111 | Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus | 0.2 | KE:1614 | Decrease, androgen receptor activation |
| AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.5 | KE:786 | Increase, Cytotoxicity (hepatocytes) |
| KE:787 | Increase, Regenerative cell proliferation (hepatocytes) | ||||||
| AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine system disease | - | Rattus norvegicus, Mus musculus | 0.29 | KE:279 | Thyroperoxidase, Inhibition |
| KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | ||||||
| AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Fathead minnow | 0.12 | KE:279 | Thyroperoxidase, Inhibition |
| AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | African clawed frog | 0.25 | KE:279 | Thyroperoxidase, Inhibition |
| AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal system disease | - | 0.25 | KE:1286 | Down Regulation, GSS and GSTs gene | |
| KE:1287 | Glutathione synthesis | ||||||
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.33 | KE:1502 | Histone deacetylase inhibition |
| KE:1262 | Apoptosis | ||||||
| AOP:232 | NFE2/Nrf2 repression to steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.12 | KE:1417 | NFE2/Nrf2 repression | |
| AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Mouse, Rat, Lemna minor, Human, Caenorhabditis elegans | 0.5 | KE:1821 | Decrease, Cell proliferation |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.17 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.4 | KE:1821 | Decrease, Cell proliferation | |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10008 | Increased transcription for detoxification and repair mechanism | |
| AOP:270 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity | Unclassified | - | 0.12 | KE:10008 | Increased transcription for detoxification and repair mechanism | |
| AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | Fish | 0.2 | KE:279 | Thyroperoxidase, Inhibition |
| AOP:274 | Histone deacetylase inhibition leads to impeded craniofacial development | Musculoskeletal system disease | - | 0.25 | KE:1502 | Histone deacetylase inhibition | |
| AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural tube defect | - | 0.2 | KE:1502 | Histone deacetylase inhibition | |
| AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | Human | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal system disease | Under Review | Homo sapiens | 0.33 | KE:1753 | Chronic reactive oxygen species |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:306 | Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring | Unclassified | Under Development | Rat, Human, Mouse | 0.5 | KE:1614 | Decrease, androgen receptor activation |
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune system disease; Musculoskeletal system disease | Under Development | Homo sapiens | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
| AOP:318 | Glucocorticoid Receptor activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.2 | KE:122 | Activation, Glucocorticoid Receptor | |
| AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | Fish | 0.25 | KE:1115 | Increase, Reactive oxygen species |
| AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | Daphnia magna, Paracyclopina nana | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | Daphnia magna | 0.2 | KE:1115 | Increase, Reactive oxygen species |
| AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | Daphnia magna, Daphnia middendorffiana, Daphnia pulex, Daphnia pulicaria, Daphnia parvula | 0.33 | KE:1821 | Decrease, Cell proliferation |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.4 | KE:1821 | Decrease, Cell proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.6 | KE:1821 | Decrease, Cell proliferation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:334 | Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration | Unclassified | - | Teleost fish | 0.17 | KE:122 | Activation, Glucocorticoid Receptor |
| AOP:344 | Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring | Unclassified | Under Development | 0.5 | KE:1614 | Decrease, androgen receptor activation | |
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine system disease; Reproductive system disease; Reproductive system disease | Under Development | Mammals | 0.33 | KE:1614 | Decrease, androgen receptor activation |
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | Zebrafish | 0.12 | KE:279 | Thyroperoxidase, Inhibition |
| AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.12 | KE:279 | Thyroperoxidase, Inhibition | |
| AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.12 | KE:279 | Thyroperoxidase, Inhibition | |
| AOP:372 | Androgen receptor antagonism leading to testicular cancer | Endocrine system disease; Reproductive system disease; Cancer | - | 0.4 | KE:1614 | Decrease, androgen receptor activation | |
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.17 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign neoplasm; Endocrine system disease; Reproductive system disease; Reproductive system disease; Cancer; Endocrine system disease | Under Development | Human, Rat, Mice | 0.22 | KE:1046 | Suppression, Estrogen receptor (ER) activity |
| KE:1973 | Increased, estrogens | ||||||
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive system disease | - | 0.12 | KE:1065 | Activation, estrogen receptor alpha | |
| AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory system disease | - | 0.1 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1262 | Apoptosis | ||||||
| AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular system disease | - | 0.06 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal system disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal system disease | - | 0.18 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1262 | Apoptosis | ||||||
| AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal system disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:472 | DNA adduct formation leading to kidney failure | Urinary system disease | - | 0.11 | KE:1115 | Increase, Reactive oxygen species | |
| AOP:477 | Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring | Physical disorder | - | 0.67 | KE:1614 | Decrease, androgen receptor activation | |
| KE:26 | Antagonism, Androgen receptor | ||||||
| AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive disorder | - | Human | 0.29 | KE:1869 | Diminished protective oxidative stress response |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired metabolic disease | - | Mus musculus, Homo sapiens | 0.1 | KE:2126 | Estrogen receptor alpha inactivation |
| AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited metabolic disorder; Disease of metabolism | - | 0.25 | KE:2126 | Estrogen receptor alpha inactivation | |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive system disease; Cancer | Under Review | Human, Mouse | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.17 | KE:1417 | NFE2/Nrf2 repression |
| AOP:508 | Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway | Cardiovascular system disease | - | Mouse, Zebrafish, Human | 0.14 | KE:1417 | NFE2/Nrf2 repression |
| AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular system disease | - | 0.14 | KE:1417 | NFE2/Nrf2 repression | |
| AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular system disease | - | Human, Mouse, Zebrafish | 0.06 | KE:1115 | Increase, Reactive oxygen species |
| AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | 0.15 | KE:2217 | Binding of antagonist to glucocorticoid hormone receptor | |
| KE:2220 | Antagonism, Glucocorticoid hormone receptor | ||||||
| AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor | |
| AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor | |
| AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.22 | KE:1115 | Increase, Reactive oxygen species | |
| KE:1262 | Apoptosis | ||||||
| AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular system disease | - | 0.08 | KE:1115 | Increase, Reactive oxygen species |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.4 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species | ||||||
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.4 | KE:885 | Increase, Cancer |
| KE:1115 | Increase, Reactive oxygen species |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.